Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALTS ALT5 Sigma	$6.57 +19.2%	$7.45	$1.55 ▼ $10.95	$141.97M	2.17	10.04 million shs	13.00 million shs
IPA ImmunoPrecise Antibodies	$3.20 +21.7%	$1.70	$0.27 ▼ $3.21	$147.69M	0.49	1.69 million shs	2.99 million shs
SNYR Synergy CHC	$2.94 +1.4%	$3.23	$1.19 ▼ $10.00	$27.76M	N/A	49,557 shs	80,384 shs
ZURA Zura Bio	$2.01 +1.0%	$1.43	$0.97 ▼ $5.07	$130.69M	-0.06	391,867 shs	585,013 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALTS ALT5 Sigma	0.00%	+10.61%	-7.46%	-26.26%	+138.91%
IPA ImmunoPrecise Antibodies	0.00%	+60.00%	+38.53%	+474.40%	+259.59%
SNYR Synergy CHC	0.00%	-14.29%	-25.94%	+50.00%	+9,700.00%
ZURA Zura Bio	0.00%	+21.08%	+19.64%	+97.06%	-43.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALTS ALT5 Sigma	0.5613 of 5 stars	0.0	4.0	2.8	0.0	0.0
IPA ImmunoPrecise Antibodies	1.648 of 5 stars	2.5	3.0	3.3	0.0	0.6
SNYR Synergy CHC	4.3641 of 5 stars	3.8	0.0	2.8	3.3	3.1
ZURA Zura Bio	3.2015 of 5 stars	3.5	5.0	2.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALTS ALT5 Sigma	0.00	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	3.00	Buy	$4.00	25.00% Upside
SNYR Synergy CHC	3.50	Strong Buy	$10.00	240.14% Upside
ZURA Zura Bio	3.00	Buy	$14.00	596.52% Upside

Current Analyst Ratings Breakdown

Latest SNYR, IPA, ALTS, and ZURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$3.00 ➝ $2.00
8/15/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $16.00
8/15/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALTS ALT5 Sigma	$12.53M	11.33	N/A	N/A	$0.55 per share	11.95
IPA ImmunoPrecise Antibodies	$17.59M	8.40	N/A	N/A	$0.37 per share	8.65
SNYR Synergy CHC	$34.83M	0.80	$0.27 per share	11.05	($1.31) per share	-2.24
ZURA Zura Bio	N/A	N/A	N/A	N/A	$1.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALTS ALT5 Sigma	-$6.24M	N/A	0.00	∞	N/A	-74.89%	-179.27%	-16.28%	N/A
IPA ImmunoPrecise Antibodies	-$21.69M	-$0.68	N/A	N/A	N/A	-122.10%	-40.62%	-22.19%	9/15/2025 (Estimated)
SNYR Synergy CHC	$2.12M	$0.38	7.74	4.98	N/A	10.02%	-18.56%	20.28%	N/A
ZURA Zura Bio	-$45.39M	-$0.70	N/A	N/A	N/A	N/A	-49.11%	-40.06%	11/6/2025 (Estimated)

Latest SNYR, IPA, ALTS, and ZURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/15/2025	Q1 2026	IPA ImmunoPrecise Antibodies	-$0.04	N/A	N/A	N/A	$5.90 million	N/A
8/14/2025	Q2 2025	SNYR Synergy CHC	$0.08	$0.17	+$0.09	$0.17	$10.80 million	$6.74 million
8/14/2025	Q2 2025	ZURA Zura Bio	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A
7/29/2025	Q4 2025	IPA ImmunoPrecise Antibodies	-$0.02	-$0.04	-$0.02	-$0.04	$7.89 million	$5.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALTS ALT5 Sigma	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	N/A	N/A	N/A	N/A	N/A
SNYR Synergy CHC	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALTS ALT5 Sigma	1.45	0.88	0.88
IPA ImmunoPrecise Antibodies	0.49	2.08	1.85
SNYR Synergy CHC	N/A	2.74	1.62
ZURA Zura Bio	N/A	8.40	8.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALTS ALT5 Sigma	6.27%
IPA ImmunoPrecise Antibodies	6.70%
SNYR Synergy CHC	N/A
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
ALTS ALT5 Sigma	4.90%
IPA ImmunoPrecise Antibodies	6.83%
SNYR Synergy CHC	56.60%
ZURA Zura Bio	14.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALTS ALT5 Sigma	170	21.61 million	20.55 million	N/A
IPA ImmunoPrecise Antibodies	80	46.15 million	43.00 million	Not Optionable
SNYR Synergy CHC	40	9.44 million	4.10 million	N/A
ZURA Zura Bio	3	68.38 million	58.65 million	Optionable

SNYR, IPA, ALTS, and ZURA Headlines

Recent News About These Companies

FY2025 EPS Estimates for Zura Bio Boosted by HC Wainwright

August 23 at 7:45 AM | marketbeat.com

FY2025 EPS Estimates for Zura Bio Lifted by HC Wainwright

August 23 at 2:45 AM | americanbankingnews.com

Zura Bio (NASDAQ:ZURA) Given New $2.00 Price Target at HC Wainwright

August 21 at 8:10 AM | marketbeat.com

HC Wainwright Issues Pessimistic Forecast for Zura Bio (NASDAQ:ZURA) Stock Price

August 21 at 2:37 AM | americanbankingnews.com

Zura Bio price target lowered to $2 from $3 at H.C. Wainwright

August 19, 2025 | msn.com

Q1 Earnings Estimate for Zura Bio Issued By Leerink Partnrs

August 19, 2025 | marketbeat.com

Oppenheimer Has Lowered Expectations for Zura Bio (NASDAQ:ZURA) Stock Price

August 18, 2025 | americanbankingnews.com

Zura Bio (NASDAQ:ZURA) Price Target Cut to $16.00 by Analysts at Oppenheimer

August 17, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Earns Buy Rating from Chardan Capital

August 17, 2025 | marketbeat.com

Zura Bio's (ZURA) Buy Rating Reiterated at Chardan Capital

August 17, 2025 | americanbankingnews.com

Zura Bio (NASDAQ:ZURA) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

August 16, 2025 | marketbeat.com

Zura Bio price target lowered to $16 from $17 at Oppenheimer

August 15, 2025 | msn.com

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

August 14, 2025 | businesswire.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of "Buy" from Brokerages

August 7, 2025 | marketbeat.com

Zura Bio (ZURA) Projected to Post Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Shares Up 7.5% - What's Next?

August 6, 2025 | marketbeat.com

Robert Lisicki on Living Up to Zura Bio’s Heroic Namesake

July 31, 2025 | pharmexec.comP

3 Penny Stocks With Market Caps Over $70M Worth Watching

July 18, 2025 | finance.yahoo.com

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 | finance.yahoo.com

Zura Bio Announces Chief Financial Officer Transition

July 1, 2025 | businesswire.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SNYR, IPA, ALTS, and ZURA Company Descriptions

ALT5 Sigma NASDAQ:ALTS

$6.57 +1.06 (+19.24%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.36 +0.79 (+12.09%)

As of 08/22/2025 08:00 PM Eastern

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

ImmunoPrecise Antibodies NASDAQ:IPA

$3.20 +0.57 (+21.67%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.21 +0.01 (+0.31%)

As of 08/22/2025 07:59 PM Eastern

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Synergy CHC NASDAQ:SNYR

$2.94 +0.04 (+1.38%)

As of 08/22/2025 04:00 PM Eastern

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.

Zura Bio NASDAQ:ZURA

$2.01 +0.02 (+1.01%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.98 -0.03 (-1.44%)

As of 08/22/2025 05:24 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time